New injection could help kids with lupus avoid flares

NCT ID NCT04179032

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a weekly injection of belimumab, a drug that blocks a protein involved in lupus inflammation, in 25 children aged 5 to 17 with active lupus. The goal is to see if the drug reaches similar levels in the blood as in adults and to check its safety. If it works, it could offer a more convenient way to manage the disease at home.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belimumab (a biologic drug that blocks a protein involved in lupus inflammation)
What this could lead to: If successful, this could provide a convenient at-home injection option for children with lupus to help control their disease.
What could go wrong: This is a small, early-phase study with only 25 children, so results may not apply to all. Side effects are possible, and the drug may not work as well in kids as in adults.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

GSK Investigational Site

Cincinnati, Ohio, 45229, United States
GSK Investigational Site

Rosario, 2000, Argentina
GSK Investigational Site

Berlin, 13353, Germany
GSK Investigational Site

Saint Augustin, 53757, Germany
GSK Investigational Site

Kagoshima, 890-8520, Japan
GSK Investigational Site

Kanagawa, 216-8511, Japan
GSK Investigational Site

San Luis Potosí City, 78213, Mexico
GSK Investigational Site

Rotterdam, 3015 GJ, Netherlands
GSK Investigational Site

Barcelona, 08950, Spain
GSK Investigational Site

Madrid, 28034, Spain
GSK Investigational Site

Valencia, 46026, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.